Revolutionizing Nerve Injury Treatment
Our technology combines a FDA-approved biologic with a safe delivery system
NervMyo Therapeutics has developed a long-acting, injectable system for targeted delivery of small proteins.
Our lead asset provides local, sustained release of a FDA-approved biologic, insulin-like growth factor 1 (IGF-1), to improve nerve regrowth and prevent muscle wasting after nerve injury.
We have demonstrated robust efficacy in both rodents and non-human primates and are now positioned to advance into the safety studies required for clinical testing.
Founding Story
Our founding team met at the Johns Hopkins School of Medicine when Erica joined Sami’s lab as a medical student researcher. They spent years working together, including the entirety of Erica’s PhD, to address the largest unmet clinical needs in peripheral nerve injury care. After thoroughly optimizing and validating the IGF-1 Long-Acting Injectable in the lab, they founded NervMyo to bring life-changing therapeutics to patients. Erica, Sami, and their team of advisors are wholly committed to helping nerve injury patients regain their mobility so they can live fulfilling, productive, and pain-free lives.
-
CEO + Co-FounderNeuroscientist and entrepreneur with 12+ years neuroscience research experience.
-
Co-FounderAssociate Professor Plastic Surgery and Director of the Peripheral Nerve Center at Johns Hopkins. Former President of the American Society for Peripheral Nerve
20+ years peripheral nerve research
Interested in Connecting?
Fill out some info and we will be in touch shortly. Thank you for reaching out!